HLA基因多态性与乙型肝炎疫苗免疫效果和安全性的研究进展

职业与健康 ›› 2024, Vol. 40 ›› Issue (6): 856-859.

HLA基因多态性与乙型肝炎疫苗免疫效果和安全性的研究进展

王卫平, 白雨, 冯勇, 程琬然, 杨天, 邓鹏飞

上海市浦东新区疾病预防控制中心免疫预防科,复旦大学浦东预防医学研究院,上海 200136

收稿日期:2023-05-19 修回日期:2023-10-09 出版日期:2024-03-15 发布日期:2026-03-16
通信作者: 邓鹏飞,主管医师,E-mail：materdpf@163.com
作者简介:王卫平,女,医师,主要从事疾病监测与疫苗效果评价工作。
基金资助:
上海市浦东新区卫生健康委员会重点学科（PWZxk2022-25）; 上海市优秀青年人才项目（GWV-10.2-YQ38）; 上海市浦东疾控中心（复旦大学浦东预防医学研究院）专项（YJY-2024-03）; 上海市浦东新区科技发展基金项目（PKJ2023-Y34）

Research progress on HLA gene polymorphism and immune efficacy and safety of hepatitis B vaccine

WANG Weiping, BAI Yu, FENG Yong, CHENG Wanran, YANG Tian, DENG Pengfei

Department of Immunoprophylaxis,Shanghai Pudong New Area Center for Disease Control and Prevention,Pudong Institute of Preventive Medicine,Fudan University,Shanghai,200136, China

Received:2023-05-19 Revised:2023-10-09 Online:2024-03-15 Published:2026-03-16
Contact: DENG Pengfei,Physician in charge,E-mail：materdpf@163.com

摘要/Abstract

摘要： 近年来,人类白细胞抗原（human leukocyte antigen,HLA）基因在乙型肝炎疫苗免疫效果相关性被诸多医疗专家所关注。本文就HLA基因在乙型肝炎疫苗免疫效果的相关研究进行总结和归纳,探讨HLA基因多态性与乙型肝炎肝疫苗免疫反应和不良反应关系,总结不同HLA基因对乙型肝炎疫苗免疫效果的相关机制,为不同HLA人群乙型肝炎疫苗的个性化疫苗接种提供科学依据,现就HLA基因概况、乙型肝炎病毒（hepatitis B virus,HBV）疫苗应答效果及其相关机制等作一综述。

关键词: 人类白细胞抗原, 基因多态性, 乙型肝炎, 疫苗

Abstract: In recent years,the correlation of human leukocyte antigen（HLA） gene in the immune effect of hepatitis B vaccine has been concerned by many medical experts.This article summarizes the related research of HLA gene in the immune effect of hepatitis B vaccine,discusses the relationship between HLA gene polymorphism and immune response and adverse reactions of hepatitis B vaccine,summarizes the related mechanism of different HLA genes on the immune effect of hepatitis B vaccine,and provides a scientific basis for personalized vaccination of hepatitis B vaccine in different HLA populations.This article reviews the general situation of HLA gene,the response effect of HBV vaccine and its related mechanism.

Key words: Human leukocyte antigen, Gene polymorphism, Hepatitis B, Vaccine

中图分类号:

R181.3

王卫平, 白雨, 冯勇, 程琬然, 杨天, 邓鹏飞. HLA基因多态性与乙型肝炎疫苗免疫效果和安全性的研究进展. [J]职业与健康, 2024, 40(6): 856-859.

WANG Weiping, BAI Yu, FENG Yong, CHENG Wanran, YANG Tian, DENG Pengfei. Research progress on HLA gene polymorphism and immune efficacy and safety of hepatitis B vaccine. [J]OCCUPATION AND HEALTH, 2024, 40(6): 856-859.

参考文献

[1] SU S,WONG W C,ZOU Z,et al.Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China:An economic evaluation[J].Lancet Glob Health,2022,10(2):e278-e287.
[2] WHO.World Hepatitis Day Bringing hepatitis care closer to you[EB/OL].(2022-07-28)[2023-04-25].https://www.who.int/campaigns/world-hepatitis-day/2022.
[3] 杨仕贵. 消除病毒性肝炎公共卫生威胁,机遇与挑战并存[J].中华疾病控制杂志,2021,25(7):749-752.
[4] ALBERTS C J,CLIFFORD G M,GEORGES D,et al.Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country,region,and global levels:A systematic review[J].Lancet Gastroenterol Hepatol,2022,7(8):724-735.
[5] LIU J,LIANG W,JING W,et al.Countdown to 2030:eliminating hepatitis B disease,China[J].Bull World Health Organ,2019,97(3):230-238.
[6] WANG H,MEN P,XIAO Y,et al.Hepatitis B infection in the general population of China:A systematic review and meta-analysis[J].BMC Infect Dis,2019,19(1):811.
[7] PATTYN J,HENDRICKX G,Vorsters A,et al.Hepatitis B vaccines[J].J Infect Dis,2021,224(12 Suppl 2):S343-S351.
[8] LIANG X,BI S,YANG W,et al.Reprint of:Epidemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination[J].Vaccine,2013,31 Suppl 9:J21-J28.
[9] ELBAHRAWY A,ATALLA H,AlBORAIE M,et al.Recent advances in protective vaccines against hepatitis viruses:A narrative review[J].Viruses,2023,15(1):214.
[10] PAN L,ZHANG L,ZHANG W,et al.A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations[J].Hum Mol Genet,2014,23(8):2210-2219.
[11] WANG L Y,CHEN C F,WU T W,et al.Response to hepatitis B vaccination is co-determined by HLA-DPA1 and -DPB1[J].Vaccine,2019,37(43):6435-6440.
[12] BODMER W,BAILEY R A,CHARLESWORTH B,et al.The outstanding scientist,R.A.Fisher:His views on eugenics and race[J].Heredity (Edinb),2021,126(4):565-576.
[13] MAI H,CHEN J,CHEN H,et al.Fine mapping of the MHC region Identifies novel variants associated with HBV-related hepatocellular carcinoma in Han Chinese[J].J Hepatocell Carcinoma,2021,8:951-961.
[14] GARCIA-GARIJO A,FAJARDO C A,GROS A.Determinants for Neoantigen Identification[J].Front Immunol,2019,10:1392.
[15] PAASO A,JAAKOLA A,SYRJANEN S,et al.From HPV infection to lesion progression:The role of hla alleles and host immunity[J].Acta Cytol,2019,63(2):148-158.
[16] WEISKOPF D,SETTE A.T-cell immunity to infection with dengue virus in humans[J].Front Immunol,2014,5:93.
[17] OVSYANNIKOVA I G,DHIMAN N,JACOBSON R M,et al.Human leukocyte antigen polymorphisms:Variable humoral immune responses to viral vaccines[J].Expert Rev Vaccines,2006,5(1):33-43.
[18] AURELI A,CANOSSI A,DEL B T,et al.HLA-DRB1*13:01 allele in the genetic susceptibility to colorectal carcinoma[J].Int J Cancer,2015, 136(10):2464-2468.
[19] STINGL J K,GRUBIC Z,JAKUPIC J,et al.The distribution of HLA-DRB3 alleles among HLA-DRB1*03:01-positive haplotypes[J].HLA,2018,92(3):160-163.
[20] GASEITSIWE S,VALENTINI D,MAHDAVIFAR S,et al.Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101,DRB1*1501,and DRB1*0401[J].Clin Vaccine Immunol,2010,17(1):168-175.
[21] STONE C J,RUKASIN C,BEACHKOFSKY T M,et al.Immune-mediated adverse reactions to vaccines[J].Br J Clin Pharmacol,2019,85(12):2694-2706.
[22] VISTE R,LIE B A,VIKEN M K,et al.Narcolepsy type 1 patients have lower levels of effector memory CD4(+) T cells compared to their siblings when controlling for H1N1-(Pandemrix)-vaccination and HLA DQB1 *06:02 status[J].Sleep Med,2021,85:271-279.
[23] AMIRZARGAR A A,MOHSENI N,SHOKRGOZAR M A,et al.HLA-DRB1,DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine[J].Iran J Immunol,2008,5(2):92-99.
[24] DENG Y,LI P,LIU W,et al.The genetic polymorphism down-regulating HLA-DRB1 enhancer activity facilitates HBV persistence,evolution and hepatocarcinogenesis in the Chinese Han population[J].J Viral Hepat,2020,27(11):1150-1161.
[25] NISHIDA N,SUGIYAMA M,SAWAI H,et al.Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine[J].Hepatology,2018,68(3):848-858.
[26] CUN Y,SHI L,KULSKI J K,et al.Haplotypic associations and differentiation of MHC class II polymorphic alu insertions at five loci with HLA-DRB1 alleles in 12 minority ethnic populations in China[J].Front Genet,2021,12:636236.
[27] CHUNG S J,KANG D Y,LEE W,et al.HLA-DRB1*15:02 Is Associated With Iodinated Contrast Media-Related Anaphylaxis[J].Invest Radiol,2020,55(5):304-309.
[28] 韦柯利,陈务卿,吴继周,等.HLA-DRB1*09/12/15与广西HBV相关性肝病的关系[J].世界华人消化杂志,2012,20(27):2570-2575.
[29] YU R B,HONG X,DING W L,et al.The association between the genetic polymorphism of HLA-DQA1,DQB1,and DRB1 and serum alanine aminotransferase levels in chronic hepatitis C in the Chinese population[J].J Gastroenterol Hepatol,2008,23(9):1394-1402.
[30] OKADA Y,UNO N,SATO S,et al.Strong influence of human leukocyte antigen-DP variants on response to hepatitis B vaccine in a Japanese population[J].Vaccine,2017,35(42):5662-5665.
[31] SINGH R,KAUL R,KAUL A,et al.A comparative review of HLA associations with hepatitis B and C viral infections across global populations[J].World J Gastroenterol,2007,13(12):1770-1787.
[32] XU B,ZHU D,BI Y,et al.Minimal association of alleles of human leukocyte antigen class II gene and long-term antibody response to hepatitis B vaccine vaccinated during infancy[J].Vaccine,2017,35(18):2457-2462.
[33] ALBAYRAK A,ERTEK M,TASYARAN M A,et al.Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey[J].Biochem Genet,2011,49(3-4):258-269.
[34] YOSRY A,FOUAD R,MAHMOUD S,et al.The association of HLA class II DR B1 alleles with HCV infection in Egyptian children[J].Arab J Gastroenterol,2011,12(1):25-28.
[35] FRANK K,PAUST S.Dynamic natural killer cell and t cell responses to influenza infection[J].Front Cell Infect Microbiol,2020,10:425.
[36] NISHIDA N,SUGIYAMA M,Ohashi J,et al.Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines[J].Sci Rep,2021,11(1):3703.
[37] WANG L,ZOU Z Q,WANG K.Clinical relevance of HLA gene variants in HBV infection[J].J Immunol Res,2016,2016:9069375.
[38] SANDALOVA E,LACCABUE D,BONI C,et al.Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans[J].PLoS Pathog,2010,6(8):e1001051.
[39] HU F,LIU X,ZHANG L,et al.Novel findings of HLA association with anti-LGI1 encephalitis:HLA-DRB1*03:01 and HLA-DQB1*02:01[J].J Neuroimmunol,2020,344:577243.
[40] BERTOLETTI A,MAINI M K.Protection or damage:A dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection[J].Curr Opin Microbiol,2000,3(4):387-392.
[41] OVSYANNIKOVA I G,PANKRATZ V S,VIERKANT R A,et al.Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine[J].J Infect Dis,2006,193(5):655-663.